准分子激光辅助非阻断吻合系统在冠状动脉旁路移植术中的首项前瞻性安全性和有效性试验
该单中心单臂前瞻性试验纳入71例患者,使用ELANA吻合系统构建LITA至LAD的远端吻合,必要时附加手工吻合。1年器械相关MACE为2.9%,总体MACE为8.7%;6个月LITA通畅率为92.5%。结论认为ELANA装置安全有效,但需长期随访确认。
要点
- ELANA装置构建LITA-LAD吻合的1年器械相关MACE为2.9%。
- 6个月LITA通畅率92.5%,FG A型40.6%、B型51.6%、O型7.8%。
- 1年总体MACE为8.7%,需长期随访确认装置效果。
核心结论
- ELANA装置在CABG中构建远端吻合安全有效,但需长期随访确认。
研究设计与样本
- 单中心、单臂、前瞻性试验,2023年6月至2024年8月纳入71例患者,89%为男性,年龄71.0±6.5岁。
- 使用ELANA吻合系统构建LITA至LAD吻合,必要时附加手工吻合。
主要发现
- 1年器械相关MACE为2.9%,包括心源性死亡和因LITA失败导致的心肌梗死。
- 1年总体MACE为8.7%。
- 6个月LITA通畅率为92.5%,FG标准A型40.6%、B型51.6%、O型7.8%。
- 对6例FG B型患者行血管内超声检查,未发现显著狭窄。
临床怎么用
- ELANA装置可用于CABG中构建LITA-LAD远端吻合,但需长期随访评估。
- 需进一步试验探究该装置是否有助于微创CABG入路的实施。
局限性
- 单中心、单臂设计,样本量有限,需长期随访确认结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Coronary artery bypass surgery (CABG) is the most common technique in cardiac surgery. Distal anastomoses are currently almost exclusively hand-sewn, which limits the widespread implementation of less-invasive approaches. The aim of this trial is to investigate the safety and effectiveness of the excimer laser-assisted nonocclusive anastomosis (ELANA) device to construct distal anastomoses in CABG. METHODS: This study is a single-center, single-arm, prospective trial. Eligible patients were included from June 2023 to August 2024. The left internal thoracic artery (LITA) to left anterior descending (LAD) anastomosis was constructed using the ELANA anastomotic system, with additional hand-sewn anastomoses if required. The primary outcome was device-related major adverse cardiac events (MACE; consisting of cardiac death, and myocardial infarction [MI] or repeat revascularization of the LAD territory) at 1 year. Secondary outcomes included 6-month LITA patency assessed by coronary angiography defined by FitzGibbon (FG) criteria and 1-year overall MACE (composite death, MI, and repeat revascularization of all coronary artery territories). RESULTS: In total, 71 patients (89% male, aged 71.0 ± 6.5 years) were included. One-year device-related MACE was 2.9%, consisting of cardiac death and MI due to LITA failure, whereas overall MACE was 8.7%. Six-month LITA patency was 92.5%: FG criteria A 40.6%, B 51.6%, and O 7.8%. Intravascular ultrasound was performed in 6 patients with FG B, which revealed no significant stenosis. CONCLUSIONS: This trial demonstrates the safety and effectiveness of the ELANA device, but long-term follow-up is needed to confirm this. Trials are needed to investigate whether this device facilitates less-invasive approaches in CABG.
引用
- Beukers SHQ, Jacobs S, Klein P, et al. The first prospective safety and effectiveness trial of the excimer laser assisted nonocclusive anastomosis system in coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2026. PMID: 42331280. doi:10.1016/j.jtcvs.2026.05.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。